

CONVERSATION RECORD
(time) (date)

TIME | DATE

1/15/14

VISIT F CONFERENCE TELEPHONE X

F INCOMING
X OUTGOING

NAME OF PERSON(S) CONTACTED OR IN CONTACT ORGANIZATION (OFFICE, DEPT. ETC.) TELEPHONE NO.
Richard Granberg, RSO MPI Research, Inc. 269-668-3336
X2050

SUBJECT

C/N 582622 (letter dated 12/4/13) – amendment to include activation products from a cyclotron that will be purchased from Pfizer and stored under MPI's license pending receipt of a new production license issued to MPI.

SUMMARY

Please submit the following information prior to receiving authorization for receipt and storage of the cyclotron and associated activated products:

1. Results of the most recent survey for radiation levels around the self-shielded cyclotron performed by Pfizer.
2. Results of the most recent survey for removable contamination conducted on the self-shielded cyclotron performed by Pfizer.
3. A commitment that MPI will submit results of radiation level surveys around the self-shielded cyclotron performed by MPI after MPI receives and installs the device.
4. A commitment that MPI will submit results of radiation level surveys in rooms/areas adjacent to the room where the cyclotron will be stored after the cyclotron is enclosed in its room at MPI.

We also discussed a proposed action plan with regard to financial assurance for the activated products associated with the cyclotron.

Included under letter dated 12/4/13 (C/N 582622), MPI submitted a trust agreement in an amount of about \$460,000 to account for the activated products in the cyclotron while the material is authorized on the broad scope license number 21-11315-02. This is in addition to the current pending financial assurance action we have for MPI for the broad scope license (C/N 300420) in the form of a letter of credit to increase the financial assurance from \$150,000 to \$225,000.


MPI will be submitting separate stand-alone financial assurance with their new application for the cyclotron-production license, and request at that time that the trust agreement described above be canceled and returned to MPI.

Follow-up call with Richard Granberg on 1/16/14:

After further thought on the proposed financial assurance action plan described above, Mr. Granberg suggested that instead of obtaining 2 financial assurance instruments (FAI) (one for the broad scope and one for the production), MPI modify the existing FAI that covers the broad scope license to include the cost to decommission the cyclotron-production license. The adjustment of the current instrument will be addressed when MPI submits its application for the new production license. In addition, Mr. Granberg stated that MPI submitted financial assurance with its application to renew their broad scope license and included a cost estimate for the production license. _____

ACTION REQUIRED

Submit a written response to items 1 – 4 above.

NAME OF PERSON DOCUMENTING CONVERSATION SIGNATURE DATE
Kevin Null  1/15/14

ACTION TAKEN

SIGNATURE TITLE DATE